Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.

Nuvalent (NUVL) has scheduled a webcast to present pivotal data from its Phase 1/2 ALKOVE-1 study. The presentation will focus on an investigational ALK-selective inhibitor for advanced non-small cell ...

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced it will be presenting new data ...

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...

Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in ...

Alterity has presented promising phase II trial data of lead compound ATH434 in multiple system atrophy at an international ...

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral ...

Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

Rubrik posts strong FQ2 2026 growth with 57% cloud ARR, a growing customer base, and a data security role supporting upside.

Background Hypothyroidism has been suggested as a predisposing and prognostic factor in patients with spontaneous coronary ...